Peptide Library

FDA-approved

Bones & muscles

Vosoritide

Evidence

FDA approved

Class

C-type natriuretic peptide analog

/

Vosoritide

KEY TAKEAWAY

Vosoritide is a 39-amino-acid analog of C-type natriuretic peptide. It is sold as Voxzogo. The FDA approved vosoritide (Voxzogo) in 2021 to increase growth in children with achondroplasia whose growth plates are still open.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

C-type natriuretic peptide analog

Approved for

Achondroplasia in children

Key fact

The FDA approved vosoritide (Voxzogo) in 2021 to increase growth in children with achondroplasia whose growth plates are still open.

Route

Daily subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Vosoritide is a 39-amino-acid analog of C-type natriuretic peptide. It is sold as Voxzogo.

How it works

How it works

It stimulates growth-plate cartilage to grow by activating the natriuretic peptide receptor B.

Regulatory status

Regulatory status

The FDA approved vosoritide (Voxzogo) in 2021 to increase growth in children with achondroplasia whose growth plates are still open.

What it is used for

What it is used for

Achondroplasia in children.

Side effects and risks

Side effects and risks

Injection-site reactions, low blood pressure and vomiting are the most common effects.

Citations

Citations

U.S. FDA prescribing information for Vosoritide. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo